Matthews International Capital Management Lowers stake in China Biologic Products Inc (CBPO)

China Biologic Products Inc (CBPO) : Matthews International Capital Management reduced its stake in China Biologic Products Inc by 64.34% during the most recent quarter end. The investment management company now holds a total of 33,500 shares of China Biologic Products Inc which is valued at $4,208,940 after selling 60,454 shares in China Biologic Products Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.China Biologic Products Inc makes up approximately 0.17% of Matthews International Capital Management’s portfolio.

Other Hedge Funds, Including , Thomas White International Ltd boosted its stake in CBPO in the latest quarter, The investment management firm added 8,076 additional shares and now holds a total of 43,718 shares of China Biologic Products Inc which is valued at $5,492,730. China Biologic Products Inc makes up approx 0.79% of Thomas White International Ltd’s portfolio. Baillie Gifford Co added CBPO to its portfolio by purchasing 1,460,752 company shares during the most recent quarter which is valued at $185,500,896. China Biologic Products Inc makes up approx 0.31% of Baillie Gifford Co’s portfolio.Gsa Capital Partners Llp boosted its stake in CBPO in the latest quarter, The investment management firm added 1,320 additional shares and now holds a total of 41,815 shares of China Biologic Products Inc which is valued at $5,610,319. China Biologic Products Inc makes up approx 0.29% of Gsa Capital Partners Llp’s portfolio. Spot Trading L.l.c added CBPO to its portfolio by purchasing 6,197 company shares during the most recent quarter which is valued at $747,048. China Biologic Products Inc makes up approx 0.10% of Spot Trading L.l.c’s portfolio.Agf Investments boosted its stake in CBPO in the latest quarter, The investment management firm added 133,131 additional shares and now holds a total of 133,245 shares of China Biologic Products Inc which is valued at $16,062,685. China Biologic Products Inc makes up approx 0.18% of Agf Investments’s portfolio.

China Biologic Products Inc closed down -0.38 points or -0.33% at $114.43 with 2,43,530 shares getting traded on Tuesday. Post opening the session at $115.46, the shares hit an intraday low of $114.24 and an intraday high of $116.56 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, China Biologic Products Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.18. The company had revenue of $91.42 million for the quarter, compared to analysts expectations of $87.58 million. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.

China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *